Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc news

   Watch this stock
Showing stories 1 - 10 of about 124   

Articles published

GSK 1,591.36 +31.86 (2.04%)
price chart
GlaxoSmithKline plc 1.7% Potential Decrease Indicated by Credit Suisse
GlaxoSmithKline plc with EPIC/TICKER LON:GSK has had its stock rating noted as 'Reiterates' with the recommendation being set at 'NEUTRAL' this morning by analysts at Credit Suisse.
GlaxoSmithKline plc (GSK) Rating Reiterated by Credit Suisse  The Cerbat Gem
GlaxoSmithKline plc (GSK) Stock Rating Reaffirmed by BNP Paribas  Community Financial News
3 Stocks That Could Surge In Q3! Randgold Resources Limited, GlaxoSmithKline ...
I've been sceptical over the durability of rocketing gold prices in 2016, and with it the share price gains enjoyed by the likes of Randgold Resources (LSE: RRS).
Two Stocks within Analysts Review: Galena Biopharma, Inc. (NASDAQ:GALE ...
On 6/29/2016, Galena Biopharma, Inc. (NASDAQ:GALE) ended trading session lower at $0.35 with -82.76%. The company traded a volume of 79.88 million shares as comparison to average volume of 3.1 million shares.
Should you buy Tesco plc, Lloyds Banking Group plc and GlaxoSmithKline plc?
Glaxo has had a tough time of late as blockbuster drugs finish patents, which has caused cash flow to decrease. The company has moved to offset this and now has an exciting pipeline of new drugs and treatments set to hit the market in the next few years.
GlaxoSmithKline plc and Royal Dutch Shell plc: 2 income champions to protect ...
GlaxoSmithKline(LSE: GSK) is one such company. The pharmaceuticals giant is a world leader in the production of consumer pharmaceutical products, such as over-the-counter medicines, toothpaste and painkillers.
Could Brexit crush 5%+ yields at GlaxoSmithKline plc and at Admiral Group plc?  Motley Fool UK
Why GlaxoSmithKline plc looks set to be beaten by Inmarsat Plc
The well-reported patent-cliff headaches of recent years have made it more difficult for GlaxoSmithKline to grow as lines with high earnings lost patent exclusivity and profits plunged.
Credit Suisse Gives GlaxoSmithKline PLC Price Target With Potential -2.83 ...
Credit Suisse gave the share price of GlaxoSmithKline PLC a price target of 1440 meaning the broker expects a potential downside of -2.83% from GlaxoSmithKline PLC's current market price of 1482. GlaxoSmithKline PLC has 4,858,000,000 shares ...
GlaxoSmithKline plc (GSK) Given "Hold" Rating at Deutsche Bank  The Cerbat Gem
Shares of GlaxoSmithKline PLC (NYSE:GSK) Sees Large Inflow of Net Money Flow  Trade Calls
GlaxoSmithKline PLC (NYSE:GSK) Updated Price Targets
02/04/2016 - GlaxoSmithKline PLC had its “market perform” rating reiterated by analysts at Sanford C. Bernstein. They now have a USD 45 price target on the stock.
GlaxoSmithKline plc vs Smith & Nephew plc: which is the FTSE 100's best ...
And for 'Big Pharma' plays like GlaxoSmithKline this is a particular problem. The Brentford firm has seen earnings steadily sink during the past five years as key labels have lost patent protection.
Should you buy into the pharma boom with GlaxoSmithKline plc and Shire plc?
There's been much talk in recent years of GlaxoSmithKline's drugs pipeline. There have been several medicine launches in recent years, yet none has turned into a blockbuster to match the success of treatments like Zantac.